Arno Therapeutics Selects Leica Biosystems To Develop Companion Diagnostic For Targeted Oncology Therapy Onapristone

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J. and NEWCASTLE UPON TYNE, England, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI); (Arno), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, and Leica Biosystems (LBS), a global leader in pathology workflow solutions and automation, announced that the companies have entered into a co-development agreement for the development of a companion diagnostic (CDx) for Arno's lead compound and personalized therapy, onapristone.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC